In an randomized clinical trial, Owen et al. demonstrated that GH improved the ovarian response to conventional ovarian stimulation regimens in females with poor ovarian responses, with significantly (P < 0.05) more follicles and more oocytes obtained in patients with polycystic ovaries when GH (24 IU) was administered on alternate days concurrently with the gonadotrophin treatment after enrollment (59). This evidence concerns the gene GH1 and polycystic ovary syndrome.